Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
RA CAPITAL MANAGEMENT L.P. | 5,614,428 9.200% |
1,056,561 (+23.18%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | scPharmaceuticals Inc. SCPH |
RA CAPITAL MANAGEMENT L.P. | 6,691,770 9.840% |
3,172,772 (+90.16%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Orchard Therapeutics plc ORTX |
RA CAPITAL MANAGEMENT L.P. | 969,479 7.700% |
-262,042 (-21.28%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | ChemoCentryx, Inc. CCXI |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-4,776,548 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
RA CAPITAL MANAGEMENT L.P. | 3,593,052 8.200% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
RA CAPITAL MANAGEMENT L.P. | 2,282,173 7.000% |
367,239 (+19.18%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Xilio Therapeutics, Inc. XLO |
RA CAPITAL MANAGEMENT L.P. | 2,002,217 7.300% |
469,450 (+30.63%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
RA CAPITAL MANAGEMENT L.P. | 4,871,067 9.700% |
692,000 (+16.56%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-5,368,451 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Otonomy, Inc. OTIC |
RA CAPITAL MANAGEMENT L.P. | 5,600,000 9.900% |
2,507,706 (+81.10%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Seres Therapeutics, Inc. MCRB |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-235,110 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | MacroGenics, Inc. MGNX |
RA CAPITAL MANAGEMENT L.P. | 6,103,594 9.960% |
1,728,377 (+39.50%) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Phathom Pharmaceuticals, Inc. PHAT |
RA CAPITAL MANAGEMENT L.P. | 3,115,008 9.900% |
-710,000 (-18.56%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Ascendis Pharma A/S ASND |
RA CAPITAL MANAGEMENT L.P. | 7,567,900 13.300% |
1,702,562 (+29.03%) |
Filing History |
| 2022-02-14 4:11 pm Unchanged |
2021-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
RA CAPITAL MANAGEMENT L.P. | 2,150,404 5.300% |
0 (Unchanged) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | Zogenix, Inc. ZGNX |
RA CAPITAL MANAGEMENT L.P. | 3,333,700 6.000% |
-2,011,931 (-37.64%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
RA CAPITAL MANAGEMENT L.P. | 1,262,193 9.700% |
1,262,193 (New Position) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Nautilus Biotechnology, Inc. NAUT |
RA CAPITAL MANAGEMENT L.P. | 2,436,430 2.000% |
2,436,430 (New Position) |
Filing History |
| 2022-02-14 4:11 pm Sale |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-3,500,000 (Position Closed) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Tango Therapeutics, Inc. TNGX |
RA CAPITAL MANAGEMENT L.P. | 2,250,000 2.600% |
2,250,000 (New Position) |
Filing History |